RNS Number:3807N
Ferraris Group PLC
10 July 2003


For immediate release                                            10th July 2003


    Not for release, distribution or publication in or into the USA, Canada,
                          Ireland, Australia or Japan


                               FERRARIS GROUP PLC
      COMPLETION OF ACQUISITION OF BIONOSTICS, INC. AND BOARD APPOINTMENTS


On 7 July 2003, Ferraris Group plc (the "Company" or "Ferraris") announced that
the resolutions to approve the acquisition of Bionostics, Inc. for a total
consideration of $31.0m (approximately #18.7m), and to implement the Placing and
Open Offer to partially finance this acquisition had been passed at an
Extraordinary General Meeting. All conditions for the Acquisition and the
Placing and Open Offer have now been satisfied and completion of the Acquisition
took place yesterday as expected.

As announced on 13 June 2003, Bruce Blessington, CEO of Bionostics, and Dr
Gerald Moller, the former CEO of Boehringer Mannheim, have now joined the Board
of Ferraris with immediate effect following completion of the Acquisition. Mr
Blessington has been appointed as an executive director and Chief Operating
Officer of Ferraris and Dr Moller joins as a non-executive director.


Enquiries

Ferraris Group plc
Steven Mills, Chief Executive                Tel: 0121 782 6000

Nomura International
Charles Spicer/Steve Adkin                   Tel: 020 7521 2000

Investec
Keith Anderson/Michael Ansell                Tel: 020 7597 5970

Binns & Co PR Ltd
Peter Binns/Emmie Peryer                     Tel: 020 7786 9600


Nomura International plc is acting exclusively for Ferraris in relation to the
Acquisition and the Placing and the Open Offer and is not advising any other
person or treating any other person as its client in relation thereto, and will
not be responsible to any person other than Ferraris for providing the
protections afforded to its clients nor for providing advice in relation to the
Acquisition, the Placing or the Open Offer.

Investec Securities is acting exclusively for Ferraris in relation to the
Placing and is not advising any other person or treating any other person as its
client in relation thereto, and will not be responsible to any person other than
Ferraris for providing the protections afforded to its clients nor for providing
advice in relation to the Placing.

The Directors and Proposed Directors (bring Bruce Blessington and Dr Gerald
Moller) of Ferraris accept responsibility for the information contained in this
announcement. To the best of the knowledge and belief of the Directors and the
Proposed Directors (who have taken all reasonable care to ensure that such is
the case) the information contained in this announcement is in accordance with
the facts and does not omit anything likely to affect the import of such
information.

This announcement does not constitute or form part of any offer or invitation to
sell or issue, or the solicitation of any offer to subscribe for, the New
Shares, the Vendor Placing Shares or the Consideration Shares in any
jurisdiction in which such offer or solicitation is unlawful. The New Shares,
the Vendor Placing Shares and the Consideration Shares have not been, and will
not be, registered under the US Securities Act of 1933 (as amended), under the
securities laws of any state of the US or under the applicable securities laws
of Canada, Ireland, Australia or Japan. Accordingly, unless an exemption under
any applicable law is available, the New Shares, the Vendor Placing Shares and
the Consideration Shares may not be offered, sold, transferred, taken up or
delivered, directly or indirectly, in the US, Canada, Ireland, Australia or
Japan or any other country outside the United Kingdom where such distribution
may lead to a breach of any legal or regulatory requirement.



                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
ACQSSIFAUSDSEFW